Futura Medical PLC Director/PDMR Shareholding (5459K)
22 Abril 2020 - 9:13AM
UK Regulatory
TIDMFUM
RNS Number : 5459K
Futura Medical PLC
22 April 2020
22 April 2020
Futura Medical plc
Director Shareholding
Futura Medical Plc (AIM: FUM) ("Futura" or "the Company") today
received notification that on 22 April 2020, James Barder, the
Company's CEO, sold 173,000 ordinary shares of 0.2 pence in the
Company ("Ordinary Shares") at a price of 11.50 pence per share and
repurchased 173,000 Ordinary Shares at a price of 11.52 pence per
share. These trades were carried out as part of a "Bed and ISA"
process, allowing James to move his existing shareholding into an
ISA.
Following these trades James Barder's beneficial holding remains
unchanged at 1,093,472 ordinary shares with an aggregate beneficial
and non-beneficial holding of 1,210,972 Ordinary Shares,
representing 0.49 per cent. of the current total voting rights of
the Company. James Barder also has options over 1,750,000 Ordinary
Shares.
Further details are contained within the notification below,
made in accordance with Article 19 of the EU Market Abuse
Regulation 596/2014.
For further information please contact:
Futura Medical plc
James Barder, Chief Executive
Angela Hildreth, Finance Director and COO
Email: Investor.relations@futuramedical.com
Tel: +44 (0) 1483 685 670
Nominated Adviser and Sole Broker:
Liberum
Bidhi Bhoma/ Euan Brown/ Kane Collings
Tel: +44 (0) 20 3100 2000
For media enquiries please contact:
Optimum Strategic Communications
Mary Clark/ Eva Haas/ Hollie Vile
Email: futuramedical@optimumcomms.com
Tel: +44 (0) 203 950 9144
Notes to editors:
About Futura Medical plc
Futura Medical plc (AIM: FUM), is a pharmaceutical company
developing a portfolio of innovative products based on its
proprietary, transdermal DermaSys(R) technology. Each DermaSys(R)
formulation is separately patented and specifically tailored for
the selected indication and application, as well as being optimised
for clinical efficacy, safety, administration and patient
convenience. The products are developed for the prescription and
consumer healthcare markets as appropriate. Current therapeutic
areas are sexual health, including erectile dysfunction, and pain
relief. Development and commercialisation strategies are designed
to maximise product differentiation and value creation whilst
minimising risk.
MED3000 is Futura's topical gel formulation that is a
breakthrough treatment for erectile dysfunction (ED) through a
unique evaporative mode of action. Futura has conducted a Phase 3
study using MED3000 in ED, referred to as "FM57". This was a 1,000
patient, dose-ranging, multi-centre, randomised, double blind,
placebo-controlled, home use, parallel group study delivering
highly statistically significant results compared to pre-treatment
baseline, consistently meeting all co-primary endpoints of IIEF,
SEP2 and SEP3 (internationally accepted clinical trial endpoints in
ED) with over 60% of patients experiencing a clinically meaningful
improvement in their ED. MED3000 also begins to work immediately in
some patients, with 60% of patients seeing onset of their erection
within 10 minutes of application.
Futura is based in Guildford, Surrey, and its shares trade on
the AIM market of the London Stock Exchange.
www.futuramedical.com
Notification and public disclosure of transactions by persons
discharging managerial responsibilities and persons closely
associated with them
1 Details of the person discharging managerial responsibilities
/ person closely associated
a) Name James Barder
-------------------------------- -------------------------------------------
2 Reason for the notification
-----------------------------------------------------------------------------
a) Position/status CEO
-------------------------------- -------------------------------------------
b) Initial notification Initial
/Amendment
-------------------------------- -------------------------------------------
3 Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
-----------------------------------------------------------------------------
a) Name Futura Medical Plc
-------------------------------- -------------------------------------------
b) LEI 21380053QLT46UNV2303
-------------------------------- -------------------------------------------
4 Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of transaction;
(iii) each date; and (iv) each place where transactions
have been conducted
-----------------------------------------------------------------------------
a) Description of the Ordinary Shares of 0.2 pence
financial instrument,
type of instrument
Identification code ISIN: GB0033278473
b) Nature of the transaction Transfer of 173,000 Ordinary Shares,
via sale and repurchase
-------------------------------- -------------------------------------------
c) Price(s) and volume(s)
------------- ------------------------
Price(s) Volume(s)
------------- ------------------------
11.50p 173,000 (sale)
------------- ------------------------
11.52p 173,000 (purchase)
------------- ------------------------
d) Aggregated information
- Aggregated volume 173,000 (sale)
- Price 11.50p
- Total GBP19,895.00
- Aggregated volume 173,000 (purchase)
- Price 11.52p
- Total GBP19,929.60
e) Date of the transaction 22 April 2020
f) Place of the transaction London Stock Exchange, AIM Market
(XLON)
-------------------------------- -------------------------------------------
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
DSHFLFLSSIIFFII
(END) Dow Jones Newswires
April 22, 2020 10:13 ET (14:13 GMT)
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Futura Medical (LSE:FUM)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
